<DOC>
	<DOCNO>NCT00033696</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy radiation therapy treat patient limited-stage small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete overall response rate patient limited stage small cell lung cancer treat induction chemotherapy comprise paclitaxel , topotecan , etoposide follow consolidation chemoradiotherapy . - Determine toxicity regimen patient . - Determine overall failure-free survival patient treat regimen . - Determine overall ( partial complete ) response rate patient treat induction chemotherapy regimen . OUTLINE : This multicenter study . - Induction therapy : Patients receive paclitaxel IV 3 hour day 1 22 , oral topotecan day 2-4 23-25 , oral etoposide day 5-7 26-28 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 8 29 continue blood count recover . - Consolidation therapy : Patients receive carboplatin IV 1 hour day 43 , 64 , 85 etoposide IV 1 hour day 43-45 , 64-66 , 85-87 . Patients undergo radiotherapy daily 5 day per week begin day 43 continue 6-7 week . Patients rapid disease progression discontinue study therapy . Patients follow least every 3 month 2 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 25-60 patient accrue study within 10 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Limited stage define disease restrict one hemithorax regional lymph node metastases include hilar , ipsilateral , contralateral mediastinal lymph node Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan Lesions consider measurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion previously irradiate area No clinically suspect confirmed supraclavicular lymph node metastases No pleural effusion visible plain chest radiograph , regardless cytology PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,00/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGOT le 2 time upper limit normal ( ULN ) Renal : Creatinine great ULN Creatinine clearance great 150 mL/min men 130 mL/min woman Other : Not pregnant nursing Fertile patient must use effective contraception No currently active malignancy except nonmelanoma skin cancer Patients must complete therapy malignancy consider less 30 % risk relapse PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) consolidation therapy Chemotherapy : No prior chemotherapy small cell lung cancer No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except : Steroids adrenal failure Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) Intermittent use dexamethasone antiemetic adjunct prophylactic cranial irradiation Radiotherapy : See Disease Characteristics No prior chest radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>